Compare OPAL & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OPAL | CALC |
|---|---|---|
| Founded | 1998 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.3M | 88.3M |
| IPO Year | N/A | N/A |
| Metric | OPAL | CALC |
|---|---|---|
| Price | $2.18 | $5.60 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $2.81 | ★ $16.00 |
| AVG Volume (30 Days) | ★ 386.4K | 105.2K |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.02 | N/A |
| Revenue | ★ $329,243,000.00 | N/A |
| Revenue This Year | $17.15 | N/A |
| Revenue Next Year | $22.04 | N/A |
| P/E Ratio | $95.04 | ★ N/A |
| Revenue Growth | ★ 7.26 | N/A |
| 52 Week Low | $1.26 | $1.42 |
| 52 Week High | $4.08 | $7.20 |
| Indicator | OPAL | CALC |
|---|---|---|
| Relative Strength Index (RSI) | 45.03 | 53.61 |
| Support Level | $2.12 | $5.52 |
| Resistance Level | $2.87 | $7.20 |
| Average True Range (ATR) | 0.19 | 0.72 |
| MACD | -0.03 | -0.10 |
| Stochastic Oscillator | 27.01 | 38.75 |
OPAL Fuels Inc is a fully integrated, nationwide leader in the production and distribution of low-carbon intensity renewable natural gas. The company is also engaged in the marketing and distribution of RNG to heavy-duty trucking and other hard-to-de-carbonize industrial sectors. The company designs, develops, constructs, operates, and services Fueling Stations for trucking fleets across the country that use natural gas to displace diesel as their transportation fuel. The company derives revenue from the sale of Renewable Power, design, development, construction, and service of Fueling Stations, and sales of RNG produced by OPAL and third parties as pipeline-quality natural gas.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.